APLMW News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AP

Volume

3.95K

Loading chart

AP

APLMWApollomics Inc. Warrant

APLMW

Pay with—

Available Balance0.00

AP

Mkt Cap

$921,652

Volume

3.95K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Apollomics, Inc. Company Operational Continuity UpdateApollomics Inc. reversed its wind-up plans after receiving $4.1 million in PIPE investments, appointed a new board and management team, and remains committed to continuing its global clinical trials for APL-101 (vebreltinib), a targeted oncology therapy.GlobeNewswire Inc. · Oct 14, 2025

Nasdaq Halts Apollomics Inc., Ltd.Nasdaq Stock Market halted trading for Apollomics Inc. on September 17, 2025, at 14:37:17 Eastern Time, requesting additional information from the company.GlobeNewswire Inc. · Sep 17, 2025

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid LeukemiaApollomics announced that its Phase 3 bridging trial of uproleselan in China for relapsed or refractory acute myeloid leukemia did not demonstrate a favorable benefit, with the median overall survival being lower in the uproleselan arm compared to the chemotherapy-only arm.GlobeNewswire Inc. · Dec 20, 2024

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical ProgressApollomics reported progress in its vebreltinib program, including new data in non-CNS MET fusion tumors and NSCLC with MET amplification. The company also announced the closure of its uproleselan program due to negative Phase 3 results from its licensor, GlycoMimetics.GlobeNewswire Inc. · Aug 14, 2024

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerFOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics.GlobeNewswire Inc. · Mar 4, 2024

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price RequirementGlobeNewswire Inc. · Jan 19, 2024

Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology ConferenceFOSTER CITY, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will participate in a Fireside Chat at the B. Riley Securities 2024 Virtual Oncology Conference on Thursday, January 18, 2024 at 11:00 a.m. ET.GlobeNewswire Inc. · Jan 17, 2024

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaFOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced the completion of enrollment in its Phase 3 bridging study evaluating uproleselan (APL-106), an investigational, first-in-class E-selectin antagonist, added to a standard chemotherapy regimen for the treatment of adults with relapsed or refractory acute myeloid leukemia (relapsed/refractory AML).GlobeNewswire Inc. · Jan 3, 2024

Apollomics to Present at the 2024 Biotech ShowcaseFOSTER CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Sanjeev Redkar, Ph.D., Co-Founder and President, will present at the 2024 Biotech Showcase on Monday, January 8, 2024 at 10:30 a.m. PT at the Hilton San Francisco Union Square in San Francisco, Calif.GlobeNewswire Inc. · Jan 2, 2024

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceFOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that Guo-Liang Yu, Ph.D., Co-Founder and Chief Executive Officer of Apollomics and Sanjeev Redkar, Ph.D., Co-Founder and President, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023 at 11:30 a.m. ET.GlobeNewswire Inc. · Nov 29, 2023

to start trading

AP

APLMWApollomics Inc. Warrant

APLMW

Pay with—

Available Balance0.00

Your PositionYou don't own any APLMW yet.

Related Tickers

Earnings